Busulfan plays a critical role in conditioning regimens for hematopoietic cell transplantation and emerging gene therapies, but its narrow therapeutic window leaves little room for error. Too little can lead to graft rejection, while too much increases the risk of severe toxicity and treatment-related complications.
In this white paper, InsightRX experts explore how therapeutic drug monitoring (TDM) combined with model-informed precision dosing (MIPD) can help clinicians strike the right balance between efficacy and safety. You’ll learn how advanced Bayesian methods, continuous learning models, and clinical decision support (CDS) tools help clinicians improve dosing precision, help reduce toxicity, and make busulfan monitoring more efficient and cost-effective across patient populations.
Learn how your team can:
- Improve target attainment and support better clinical outcomes with MIPD
- Reduce sampling frequency and patient burden
- Optimize dosing strategies using adaptive, continuously learning models
Click below to download the white paper and see how InsightRX empowers safer, smarter, and more personalized busulfan therapy.
